Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

Home
/
update
/
details

Study by Tata Memorial Finds Nimotuzumab Significantly Improves Survival Rates in Head and Neck Cancer

NextEdge Admin

30 Jul 2024

3 min 4 sec

A study by Tata Memorial Hospital in Mumbai has shown that adding nimotuzumab to the standard treatment regimen significantly improves the 10-year overall survival rate for patients with locally advanced squamous cell carcinoma of the head and neck. The phase III study on 536 patients confirmed that nimotuzumab not only enhances progression-free survival but also maintains a good quality of life for long-term survivors, making it a potential therapeutic option in India.

Patients who received nimotuzumab with concurrent radiotherapy and cisplatin had a 10-year overall survival rate of 33.5%, compared to 22.5% for those who received only radiotherapy and cisplatin. The median overall survival improved from 2.78 years in the standard treatment arm to 3.69 years in the nimotuzumab arm. Additionally, there was no significant increase in late-term adverse events, underscoring the drug's safety and tolerability.

Head and neck cancers constitute a significant cancer burden in India, with over 65% of patients presenting with advanced disease requiring medical management. Currently, no other targeted therapy can be combined with concurrent chemoradiation with curative intent, marking this study as a substantial advancement.

Dr. Kumar Prabhash, Head of Medical Oncology at Tata Memorial Hospital, stated, “The findings of this study are promising for patients with head and neck cancer. Adding nimotuzumab to the existing therapy regimen significantly improves long-term survival rates while maintaining patient quality of life.” Dr. Neera Gupta of Eris Lifesciences emphasized the impact on patients' quality of life, noting that nimotuzumab improves progression-free and overall survival while preserving vital functions.

The study, initially supported by Biocon and now by Eris Lifesciences, was an open-label, investigator-initiated, phase III randomized trial conducted from 2012 to 2018. It found that nimotuzumab significantly improves long-term overall survival, particularly benefiting HPV-negative patients, without increasing the risk of long-term side effects. This represents a significant advancement in managing head and neck cancer in India.